|
Age
|
68.1 ± 7.9
|
68.2 ± 7.9
|
68.2 ± 7.9
|
0.26
|
|
Male
|
1057(92.4)
|
439(91.8)
|
520(92.9)
|
0.13
|
|
Smoking status
| | | |
0.80
|
|
Current smoker
|
348(30.4)
|
147(30.8)
|
168(30)
| |
|
Ex-smoker
|
700(61.2)
|
295(61.7)
|
340(60.7)
| |
|
Non-smokera
|
80(7.0)
|
31(6.5)
|
45(8.0)
| |
|
Pack-years
|
42.5 ± 25.1
|
43.2 ± 25.3
|
41.3 ± 24.3
|
0.26
|
|
BMI
|
23.4 ± 10.3
|
23.0 ± 3.4
|
23.0 ± 14.4
|
0.78
|
|
SGRQ
|
28.6 ± 17.0
|
33.4 ± 18.7
|
25.9 ± 15.5
|
< 0.01
|
|
CAT
|
14.2 ± 7.9
|
16.2 ± 7.9
|
12.9 ± 7.5
|
< 0.01
|
|
mMRC
|
1.4 ± 0.9
|
1.6 ± 0.9
|
1.2 ± 0.9
|
< 0.01
|
|
FVC measured, L
|
3.21 ± 0.82
|
3.03 ± 0.79
|
3.30 ± 0.79
|
< 0.01
|
|
Post-BD FEV1, L
|
1.67 ± 0.58
|
1.49 ± 0.54
|
1.75 ± 0.55
|
< 0.01
|
|
Post-BD FEV1, % predicted
|
61.37 ± 19.2
|
55.86 ± 19.12
|
63.38 ± 16.90
|
< 0.01
|
|
Post-BD FEV1/FVC ratio
|
50.88 ± 12.07
|
47.91 ± 12.25
|
52.3 ± 11.39
|
< 0.01
|
|
Bronchodilator response
| | | |
0.003
|
|
None
|
968(84.8)
|
392(82)
|
486(87.3)
| |
|
BDR > 12% and 200 ml (FEV1)
|
144(12.6)
|
66(13.8)
|
65(11.7)
| |
|
BDR > 15% and 400 ml (FEV1) (Spanish ACO)
|
29(2.5)
|
20(4.2)
|
6(1.1)
| |
|
DLco, % predicted
|
75.36 ± 30.32
|
73.92 ± 23.99
|
75.52 ± 36.12
|
0.45
|
|
Asthma
|
382(33.4)
|
205(42.9)
|
166(29.6)
|
< 0.001
|
|
Serum eosinophils cells/μlb
|
179(102–302)
|
179(108-328)
|
178(97–280)
|
0.16
|
|
Eosinophils > 300 cells/μl n (%)
|
214(18.7)
|
99(20.7)
|
95(17.0)
|
0.038
|
|
Exacerbation frequency, events/person-year
|
0.44 ± 1.61
|
0.60 ± 1.65
|
0.33 ± 1.64
|
< 0.01
|
|
0
|
909(81.2)
|
354(75.2)
|
470(85.0)
|
< 0.001
|
|
1
|
115(10.3)
|
57(12.1)
|
51(9.2)
| |
|
≥ 2
|
96(8.6)
|
60(12.7)
|
32(5.8)
| |
|
GOLD group
| | | |
< 0.01
|
|
A
|
293(25.6)
|
76(15.9)
|
179(32.0)
| |
|
B
|
680(59.4)
|
309(64.6)
|
322(57.5)
| |
|
C
|
26(2.3)
|
8(1.7)
|
15(2.7)
| |
|
D
|
115(10.1)
|
77(16.1)
|
36(6.4)
| |
